Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy

American Journal of Obstetrics and Gynecology

Volumn 183, Issue 2, 2000, Pages 511-512

  Achtari, Chahin ^a   Hohlfeld, Patrick ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Acute leukemia; Idarubicin; Pregnancy

Indexed keywords

AMOXICILLIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CEFEPIME; CYCLOPHOSPHAMIDE; CYTARABINE; IDARUBICIN; PREDNISONE; TAZOBACTAM; VINCRISTINE;

ACUTE LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CASE REPORT; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; NEWBORN; PLACENTA; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY;

EID: 0033845269     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.105964     Document Type: Article

References (2)

1. Acute leukemia and pregnancy: Fatal fetal outcome after exposure to idarubicin during the second trimester
2. Successful fetal outcome after exposure to idarubicin and cytosine-arabinoside during the second trimester of pregnancy: A case report